Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: A single-centre, open-label, phase 2 trial

The Lancet Oncology

Volumn 17, Issue 1, 2016, Pages 48-56

  Wang, Michael L ^a   Lee, Hun ^a   Chuang, Hubert ^a   Wagner Bartak, Nicolaus ^a   Hagemeister, Frederick ^a   Westin, Jason ^a   Fayad, Luis ^a   Samaniego, Felipe ^a   Turturro, Francesco ^a   Oki, Yasuhiro ^a   Chen, Wendy ^a   Badillo, Maria ^a   Nomie, Krystle ^a   Rosa, Maria DeLa ^a   Zhao, Donglu ^a   Lam, Laura ^a   Addison, Alicia ^a   Zhang, Hui ^a   Young, Ken H ^a   Li, Shaoying ^a   Santos, David ^a   Medeiros, L Jeffrey ^a   Champlin, Richard ^a   Romaguera, Jorge ^a   Zhang, Leo ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD20 ANTIGEN; CREATININE; CYCLIN D1; IBRUTINIB; KI 67 ANTIGEN; RITUXIMAB; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; ASCITES; ATRIAL FIBRILLATION; BACKACHE; BLEEDING; BLURRED VISION; BREAST HEMORRHAGE; BRONCHITIS; CARDIOMEGALY; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSPEPSIA; DYSPNEA; EPIPHORA; EPISTAXIS; FAINTNESS; FATIGUE; FEMALE; FEVER; FOLLOW UP; FRACTURE; GINGIVA DISEASE; GUM INFECTION; HEADACHE; HEPATITIS; HIP PAIN; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOMAGNESEMIA; INSOMNIA; KIDNEY DISEASE; KIDNEY INFECTION; LEG CRAMP; LEUKOCYTOSIS; LEUKOPENIA; LIMB PAIN; LUNG INFECTION; MALE; MANTLE CELL LYMPHOMA; MEMORY DISORDER; MICTURITION DISORDER; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NOSE OBSTRUCTION; OPEN STUDY; ORAL MUCOSITIS; PAIN; PENILE PAIN; PENIS DISEASE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SINUSITIS; SKIN INFECTION; SORE THROAT; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WOUND INFECTION; CHEMICALLY INDUCED; CLINICAL TRIAL; INTENTION TO TREAT ANALYSIS; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; RECURRENT DISEASE; RETREATMENT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATRIAL FIBRILLATION; DIARRHEA; EPISTAXIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTENTION TO TREAT ANALYSIS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEUTROPENIA; PYRAZOLES; PYRIMIDINES; RECURRENCE; RETREATMENT; RITUXIMAB; TREATMENT OUTCOME;

EID: 84955411773     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00438-6     Document Type: Article

References (30)

1. Jares P, Campo E Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008, 142:149-165.
2. NCCN clinical practice guidelines in oncology for non-Hodgkin's lymphoma v1.2015 National Comprehensive Cancer Network, (accessed April 22, 2015). http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf.
3. Dreyling M, Ferrero S, Hermine O How to manage mantle cell lymphoma. Leukemia 2014, 28:2117-2130.
4. LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012, 119:2093-2099.
5. Prescribing information: IMBRUVICA (ibrutinib) capsules, for oral use (accessed April 22, 2015). https://www.imbruvica.com/downloads/Prescribing_Information.pdf.
6. Buggy JJ, Elias L Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012, 31:119-132.
7. Chang BY, Francesco M, De Rooij MF, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 2013, 122:2412-2424.
8. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012, 119:2590-2594.
9. Mohamed AJ, Yu L, Backesjo CM, et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009, 228:58-73.
10. Satterthwaite AB, Witte ON The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 2000, 175:120-127.
11. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013, 369:507-516.
12. Wang M, Rule S, Martin P, et al. Single-agent ibrutinib demonstrates safety and durability of response at 2 years follow-up in patients with relapsed or refractory mantle cell lymphoma: updated results of an international, multicenter, open-label phase 2 study. Blood 2014, 124. abstr 4453.
13. Furtado M, Wang ML, Munneke B, et al. Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma. Br J Haematol 2015, 170:131-134.
14. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012, 119:1182-1189.
15. Wang M, Zhang L, Han X, et al. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 2008, 14:2154-2160.
16. Da Roit F, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica 2015, 100:77-86.
17. Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab for relapsed mantle cell lymphoma: an update from a Phase II clinical trial. Hematol Oncol 2015, 33(suppl S1):188-243.
18. Wang ML, Hagemeister F, Westin JR, et al. Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a phase II clinical trial. Blood 2014, 124. abstr 627.
19. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
20. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (accessed April 22, 2015). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf.
21. Klapper W, Hoster E, Determann O, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009, 2:103-111.
22. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014, 15:1090-1099.
23. Schluter C, Duchrow M, Wohlenberg C, et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993, 123:513-522.
24. Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012, 158:355-362.
25. Goy A, Bernstein SH, McDonald A, et al. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma 2010, 51:1269-1277.
26. He X, Chen Z, Fu T, et al. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer 2014, 14:153.
27. Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 2015, 6:1175-1179.
28. Balasubramanian S, Schaffer M, Deraedt W, et al. Mutational analysis of patients with primary resistance to single-agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL). Blood 2014, 124. abstr 21.
29. Igarashi T, Kobayashi Y, Ogura M, et al. IDEC-C2B8 Study Group in Japan. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002, 13:928-943.
30. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 study. J Clin Oncol 2013, 31:3688-3695.